Top

Published in:

01-06-2010 | Urologic Oncology

Clinical Significance of Tumor Necrosis Factor Receptor Superfamily Member 11b Polymorphism in Prostate Cancer

Authors: Bo-Ying Bao, PhD, Victor C. Lin, MD, Shu-Hung Huang, MD, Jiunn-Bey Pao, MS, Ta-Yuan Chang, PhD, Te-Ling Lu, PhD, Yu-Hsuan Lan, PhD, Lu-Min Chen, MD, Wen-Chien Ting, MD, Wen-Hui Yang, PhD, Chi-Jeng Hsieh, MS, Shu-Pin Huang, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2010

Abstract

Background

Bone metastases are the most critical complication of prostate cancer (PCa), resulting in severe morbidity and mortality. Tumor necrosis factor receptor superfamily member 11b (TNFRSF11B) is a critical regulator between PCa cells and the bone environment. Recently, TNFRSF11B rs10505346 has been implicated in PCa risk in the Cancer Genetic Markers of Susceptibility genomewide association study. However, the association between this variant and biochemical failure in PCa patients receiving radical prostatectomy (RP) has not been determined.

Methods

Associations of TNFRSF11B rs10505346 with age at diagnosis, preoperative prostate-specific antigen (PSA) level, Gleason score, pathologic stage, surgical margin, and PSA recurrence were evaluated in a cohort of 314 localized PCa patients receiving RP. The prognostic significance on PSA recurrence was assessed by Kaplan–Meier analysis and Cox regression model.

Results

The mean level of preoperative PSA and the relative risks of PSA recurrence after RP were lower in individuals with T allele than in those with the G allele at TNFRSF11B rs10505346 (P = 0.019 and 0.014, respectively). The T allele of rs10505346 remained a protective factor against PSA recurrence (P = 0.022) in multivariate Cox regression model after considering all clinicopathological risk factors except PSA level.

Conclusions

Our data suggest that TNFRSF11B rs10505346 is associated with PSA level and might be a prognostic factor for the recurrence of PSA in PCa patients receiving RP.

Available only for authorised users

Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.CrossRefPubMed

Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992;69:64–70.CrossRefPubMed

Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5.CrossRefPubMed

Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65:1710–8.CrossRefPubMed

Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001;107:1235–44.CrossRefPubMed

Brown JM, Vessella RL, Kostenuik PJ, et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001;7:2977–83.PubMed

Nyambo R, Cross N, Lippitt J, et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res. 2004;19:1712–21.CrossRefPubMed

Eaton CL, Wells JM, Holen I, et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate. 2004;59:304–10.CrossRefPubMed

Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008;371:1505–12.CrossRefPubMed

10.

Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355–65.CrossRefPubMed

11.

Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–9.CrossRefPubMed

12.

Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett. 2004;207:69–77.CrossRefPubMed

13.

Huang SP, Huang CY, Wang JS, et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res. 2007;13:6632–8.CrossRefPubMed

14.

Huang SP, Huang CY, Wu WJ, et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer. 2006;119:1902–7.CrossRefPubMed

15.

Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:3068–74.CrossRefPubMed

16.

Huang SP, Ting WC, Chen LM, et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol. 2010;17:312–22.CrossRefPubMed

17.

Huang SP, Wu WJ, Chang WS, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:2217–24.PubMed

18.

Freedland SJ, Sutter ME, Dorey F, et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365–9.CrossRefPubMed

19.

Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58–64.PubMed

20.

Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–8.CrossRefPubMed

21.

Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007;39:984–8.CrossRefPubMed

22.

Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–93.CrossRefPubMed

23.

Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst. 2008;100:962–6.CrossRefPubMed

24.

Kiemeney LA, Thorlacius S, Sulem P, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008;40:1307–12.CrossRefPubMed

25.

Narita N, Yuasa T, Tsuchiya N, et al. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer. 2008;8:224.CrossRefPubMed

26.

Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34:W635–41.CrossRefPubMed

27.

Hoang AT, Huang J, Rudra-Ganguly N, et al. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol. 2000;156:857–64.PubMed

28.

Tang D, Khaleque MA, Jones EL, et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones. 2005;10:46–58.CrossRefPubMed

29.

O’Callaghan-Sunol C, Sherman MY. Heat shock transcription factor (HSF1) plays a critical role in cell migration via maintaining MAP kinase signaling. Cell Cycle. 2006;5:1431–7.PubMed

30.

Perez-Martinez FC, Alonso V, Sarasa JL, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histol Histopathol. 2008;23:709–15.PubMed

31.

Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66–70.CrossRefPubMed

32.

Wiklund F, Zheng SL, Sun J, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009;69:419–27.CrossRefPubMed

33.

Yonou H, Horiguchi Y, Ohno Y, et al. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. Prostate. 2007;67:840–8.CrossRefPubMed

Title: Clinical Significance of Tumor Necrosis Factor Receptor Superfamily Member 11b Polymorphism in Prostate Cancer
Authors: Bo-Ying Bao, PhD
Victor C. Lin, MD
Shu-Hung Huang, MD
Jiunn-Bey Pao, MS
Ta-Yuan Chang, PhD
Te-Ling Lu, PhD
Yu-Hsuan Lan, PhD
Lu-Min Chen, MD
Wen-Chien Ting, MD
Wen-Hui Yang, PhD
Chi-Jeng Hsieh, MS
Shu-Pin Huang, MD, PhD
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-0994-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Significance of Tumor Necrosis Factor Receptor Superfamily Member 11b Polymorphism in Prostate Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Should Chemoradiotherapy Be Used in Node-Negative Esophageal or Gastric Adenocarcinoma?

Liver Resection for Multimodal Treatment of Breast Cancer Metastases: Identification of Prognostic Factors

Overexpression of Nuclear Protein Kinase CK2 β Subunit and Prognosis in Human Gastric Carcinoma

Cervical Lymph Node Dissection for Metastatic Testicular Cancer

Multicentric Study on Robotic Tumor-Specific Mesorectal Excision for the Treatment of Rectal Cancer

Prognostic Significance of c-erbB-2 and Vascular Endothelial Growth Factor in Colorectal Liver Metastases